BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 32525256)

  • 21. The role of PNPLA3 and TM6SF2 polymorphisms on liver fibrosis and metabolic abnormalities in Brazilian patients with chronic hepatitis C.
    Oliveira AIN; Malta FM; Zitelli PMY; Salles APM; Gomes-Gouvea MS; Nastri ACS; Pinho JRR; Carrilho FJ; Oliveira CP; Mendes-Corrêa MC; Pessoa MG; Mazo DF
    BMC Gastroenterol; 2021 Feb; 21(1):81. PubMed ID: 33622266
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combined effects of PNPLA3, TM6SF2 and HSD17B13 variants on severity of biopsy-proven non-alcoholic fatty liver disease.
    Paternostro R; Staufer K; Traussnigg S; Stättermayer AF; Halilbasic E; Keritam O; Meyer EL; Stift J; Wrba F; Sipos B; Canbay A; Schlattjan M; Aigner E; Datz C; Stickel F; Schafmayer C; Hampe J; Buch S; Prager G; Munda P; Mandorfer M; Ferenci P; Trauner M
    Hepatol Int; 2021 Aug; 15(4):922-933. PubMed ID: 34076851
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genetic polymorphisms associated with obesity and non-alcoholic fatty liver disease in Asian Indian adolescents.
    Jain V; Kumar A; Ahmad N; Jana M; Kalaivani M; Kumar B; Shastri S; Jain O; Kabra M
    J Pediatr Endocrinol Metab; 2019 Jul; 32(7):749-758. PubMed ID: 31216264
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association between PNPLA3 rs738409 polymorphism and nonalcoholic fatty liver disease (NAFLD) susceptibility and severity: A meta-analysis.
    Dai G; Liu P; Li X; Zhou X; He S
    Medicine (Baltimore); 2019 Feb; 98(7):e14324. PubMed ID: 30762732
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Relevance of
    Elmansoury N; Megahed AA; Kamal A; El-Nikhely N; Labane M; Abdelmageed M; Daly AK; Wahid A
    Genes (Basel); 2024 Apr; 15(4):. PubMed ID: 38674389
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Donor PNPLA3 and TM6SF2 Variant Alleles Confer Additive Risks for Graft Steatosis After Liver Transplantation.
    Míková I; Neřoldová M; Hubáček JA; Dlouhá D; Jirsa M; Honsová E; Sticová E; Lánská V; Špičák J; Trunečka P
    Transplantation; 2020 Mar; 104(3):526-534. PubMed ID: 31356578
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association of metabolic syndrome and patatin-like phospholipase 3 - rs738409 gene variant in non-alcoholic fatty liver disease among a Chennai-based south Indian population.
    Narayanasamy K; Karthick R; Panneerselvam P; Mohan N; Ramachandran A; Prakash R; Rajaram M
    J Gene Med; 2020 Apr; 22(4):e3160. PubMed ID: 31945251
    [TBL] [Abstract][Full Text] [Related]  

  • 28. TM6SF2/PNPLA3/MBOAT7 Loss-of-Function Genetic Variants Impact on NAFLD Development and Progression Both in Patients and in In Vitro Models.
    Longo M; Meroni M; Paolini E; Erconi V; Carli F; Fortunato F; Ronchi D; Piciotti R; Sabatini S; Macchi C; Alisi A; Miele L; Soardo G; Comi GP; Valenti L; Ruscica M; Fracanzani AL; Gastaldelli A; Dongiovanni P
    Cell Mol Gastroenterol Hepatol; 2022; 13(3):759-788. PubMed ID: 34823063
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PNPLA3 polymorphisms (rs738409) and non-alcoholic fatty liver disease risk and related phenotypes: a meta-analysis.
    Zhang L; You W; Zhang H; Peng R; Zhu Q; Yao A; Li X; Zhou Y; Wang X; Pu L; Wu J
    J Gastroenterol Hepatol; 2015 May; 30(5):821-9. PubMed ID: 25641744
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The APOC3 T-455C and C-482T promoter region polymorphisms are not associated with the severity of liver damage independently of PNPLA3 I148M genotype in patients with nonalcoholic fatty liver.
    Valenti L; Nobili V; Al-Serri A; Rametta R; Leathart JB; Zappa MA; Dongiovanni P; Fracanzani AL; Alterio A; Roviaro G; Daly AK; Fargion S; Day CP
    J Hepatol; 2011 Dec; 55(6):1409-14. PubMed ID: 21777557
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The roles of transmembrane 6 superfamily member 2 rs58542926 polymorphism in chronic liver disease: A meta-analysis of 24,147 subjects.
    Chen X; Zhou P; De L; Li B; Su S
    Mol Genet Genomic Med; 2019 Aug; 7(8):e824. PubMed ID: 31309745
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reduction of Caloric Intake Might Override the Prosteatotic Effects of the PNPLA3 p.I148M and TM6SF2 p.E167K Variants in Patients with Fatty Liver: Ultrasound-Based Prospective Study.
    Krawczyk M; Stachowska E; Milkiewicz P; Lammert F; Milkiewicz M
    Digestion; 2016; 93(2):139-48. PubMed ID: 26745555
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Metabolic syndrome but not genetic polymorphisms known to induce NAFLD predicts increased total mortality in subjects with NAFLD (OPERA study).
    Käräjämäki AJ; Hukkanen J; Kauma H; Kesäniemi YA; Ukkola O
    Scand J Clin Lab Invest; 2020; 80(2):106-113. PubMed ID: 31851849
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A study of genetic variants, genetic risk score and DNA methylation of PNPLA3 and TM6SF2 in alcohol liver cirrhosis.
    Shankarappa B; Mahadevan J; Murthy P; Purushottam M; Viswanath B; Jain S; Devarbhavi H; Mysore V A
    Indian J Gastroenterol; 2023 Dec; 42(6):800-807. PubMed ID: 37589914
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Possible Relevance of PNPLA3 and TLL1 Gene Polymorphisms to the Efficacy of PEG-IFN Therapy for HBV-Infected Patients.
    Enomoto H; Aizawa N; Hasegawa K; Ikeda N; Sakai Y; Yoh K; Takata R; Yuri Y; Kishino K; Shimono Y; Ishii N; Takashima T; Nishimura T; Nishikawa H; Iwata Y; Iijima H; Nishiguchi S
    Int J Mol Sci; 2020 Apr; 21(9):. PubMed ID: 32349377
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Independent and joint correlation of PNPLA3 I148M and TM6SF2 E167K variants with the risk of coronary heart disease in patients with non-alcoholic fatty liver disease.
    Wu JT; Liu SS; Xie XJ; Liu Q; Xin YN; Xuan SY
    Lipids Health Dis; 2020 Feb; 19(1):29. PubMed ID: 32093693
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association Between a Polymorphism in MBOAT7 and Chronic Kidney Disease in Patients With Biopsy-Confirmed Nonalcoholic Fatty Liver Disease.
    Koo BK; An JN; Joo SK; Kim D; Lee S; Bae JM; Park JH; Kim JH; Chang MS; Kim W
    Clin Gastroenterol Hepatol; 2020 Nov; 18(12):2837-2839.e2. PubMed ID: 31546054
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Association of single nucleotide polymorphism of SIRT1 and APOC3 with nonalcoholic fatty liver disease].
    Song X; Song C; Fan L; Ma Q; Mao J; Xu W; Li X
    Wei Sheng Yan Jiu; 2017 Jul; 46(4):527-532. PubMed ID: 29903170
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Contribution of a genetic risk score to clinical prediction of hepatic steatosis in obese children and adolescents.
    Zusi C; Mantovani A; Olivieri F; Morandi A; Corradi M; Miraglia Del Giudice E; Dauriz M; Valenti L; Byrne CD; Targher G; Maffeis C
    Dig Liver Dis; 2019 Nov; 51(11):1586-1592. PubMed ID: 31255630
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A PRISMA-compliant meta-analysis of apolipoprotein C3 polymorphisms and nonalcoholic fatty liver disease.
    Chen BF; Chien Y; Tsai PH; Perng PC; Yang YP; Hsueh KC; Liu CH; Wang YH
    J Chin Med Assoc; 2021 Oct; 84(10):923-929. PubMed ID: 34108427
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.